|By Marketwired .||
|May 15, 2014 07:00 AM EDT||
MOUNTAIN VIEW, CA--(Marketwired - May 15, 2014) - VIVUS (NASDAQ: VVUS) today announced that a poster describing results of an analysis of the association between weight loss with Qsymia
About the Presentation
Session: Diabetes/Prediabetes, Hypoglycemia, Lipid/Cardiovascular Disorders, Obesity, Reproductive Endocrinology, and Other
Abstract Title: Effect of Weight Loss on Concomitant Medication Costs in Obese/Overweight Individuals With Edmonton Obesity Staging System Stage 3 Obesity Receiving Phentermine/Topiramate Extended-Release
Authors: Timothy Church, Arya M. Sharma, Sarah A. Odeh
Date/Time: Thursday, May 15, 2014 - 9:45-11:00am PDT
Qsymia is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.
The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.
Important Safety Information
Qsymia can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy. If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.
The most commonly observed side effects in controlled clinical studies, 5% or greater and at least 1.5 times placebo, include paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.
VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health. For more information about the company, please visit www.vivus.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS's Form 10-K for the year ended December 31, 2013, as amended by the Form 10-K/A filed on April 30, 2014, and periodic reports filed with the Securities and Exchange Commission.
In most cases, it is convenient to have some human interaction with a web (micro-)service, no matter how small it is. A traditional approach would be to create an HTTP interface, where user requests will be dispatched and HTML/CSS pages must be served. This approach is indeed very traditional for a web site, but not really convenient for a web service, which is not intended to be good looking, 24x7 up and running and UX-optimized. Instead, talking to a web service in a chat-bot mode would be muc...
Feb. 11, 2016 11:15 AM EST Reads: 273
Feb. 11, 2016 11:07 AM EST
Feb. 11, 2016 11:00 AM EST Reads: 413
Feb. 11, 2016 11:00 AM EST Reads: 118
Feb. 11, 2016 11:00 AM EST Reads: 240
Feb. 11, 2016 10:33 AM EST
Feb. 11, 2016 10:30 AM EST
Feb. 11, 2016 10:15 AM EST
Feb. 11, 2016 10:00 AM EST Reads: 394
Feb. 11, 2016 09:58 AM EST
Feb. 11, 2016 09:45 AM EST
Feb. 11, 2016 09:25 AM EST
Feb. 11, 2016 09:15 AM EST Reads: 193
Feb. 11, 2016 09:00 AM EST Reads: 102
Feb. 11, 2016 08:00 AM EST Reads: 482